Induced stem cells

BrainStorm Cell Therapeutics to Announce Second Quarter Financial Results and Provide a Comprehensive Corporate Update

Retrieved on: 
Monday, August 5, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Developmental biology, Induced stem cells, Cell biology, Mesenchymal stem cell, Adult stem cell, Cellular differentiation, Draft:BrainStorm Cell Therapeutics

MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.

Key Points: 
  • MSC-NTF cells are produced from autologous, bone marrow-derived mesenchymal stem cells (MSCs) that have been expanded and differentiated ex vivo.
  • MSCs are converted into MSC-NTF cells by growing them under patented conditions that induce the cells to secrete high levels of neurotrophic factors.
  • BrainStorm is currently conducting a Phase 3 pivotal trial of autologous MSC-NTF cells for the treatment of amyotrophic lateral sclerosis (ALS).
  • About BrainStorm Cell Therapeutics Inc.
    BrainStorm Cell Therapeutics Inc. is a leading developer of innovative autologous adult stem cell therapeutics for debilitating neurodegenerative diseases.

Corrected: USRM Posts Earnings for Second Quarter 2019

Retrieved on: 
Friday, August 9, 2019
Branches of biology, Biology, Life sciences, Induced stem cells, Emerging technologies, Regenerative biomedicine, Cloning, Regenerative medicine, Tissue engineering, Stem cell

Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019.

Key Points: 
  • Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019.
  • Compared to second quarter of 2018, year-over-year revenue decreased $522k or 29%, from $1.8M to $1.2M.
  • Net decrease in gross profit margin for the second quarter 2019 was 36.8%, or $791k, compared to second quarter 2018.
  • Operating expenses were down 36.1% or $750k, for the second quarter, and also decreased for six-month ending 2019 23.8% from $3.2M to $2.5M.

R3 Stem Cell Announces 2 Day Stem Cell Training Course in Tijuana, Mexico on September 20 and 21

Retrieved on: 
Thursday, August 8, 2019
Branches of biology, Biology, Life sciences, Emerging technologies, Induced stem cells, Regenerative biomedicine, Regenerative medicine, Tissue engineering, Stem cell, Regenerative medicine

SCOTTSDALE, Ariz., Aug. 8, 2019 /PRNewswire/ --R3 Stem Cell, LLC (R3) announced that they will be offering a 2 Day Stem Cell Training Course in Mexico.

Key Points: 
  • SCOTTSDALE, Ariz., Aug. 8, 2019 /PRNewswire/ --R3 Stem Cell, LLC (R3) announced that they will be offering a 2 Day Stem Cell Training Course in Mexico.
  • The R3 Regenerative Medicine Training Course provides an educational experience for practitioners from Mexico or the United States who desire to offer stem cell and PRP procedures.
  • "We started the R3 Regenerative Medicine Training Course to give practitioners an invaluable educational course that goes step-by step through the patient's journey."
  • The R3 Stem Cell training course gives strategies on how to become a stem cell authority and emphasizes their focus on the patient's experience and journey.

USRM Posts Earnings for Second Quarter 2019

Retrieved on: 
Wednesday, August 7, 2019
Branches of biology, Biology, Life sciences, Induced stem cells, Emerging technologies, Regenerative biomedicine, Cloning, Regenerative medicine, Tissue engineering, Stem cell

Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019.

Key Points: 
  • Stem Cell, Inc. (OTC: USRM), a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions, today announced earnings for the second quarter that ended June 30, 2019.
  • Compared to second quarter of 2018, year-over-year revenue decreased $522k or 29%, from $1.8M to $1.2M.
  • Net decrease in gross profit margin for the second quarter 2019 was 36.8%, or $791k, compared to second quarter 2018.
  • Operating expenses were down 36.1% or $750k, for the second quarter, and also decreased for six-month ending 2019 23.8% from $3.2M to $2.5M.

Computer Modeling Predicts Best Stem Cell Donors and Therapies For Kids With Heart Disease

Retrieved on: 
Tuesday, August 6, 2019
Branches of biology, Biology, Life sciences, Induced stem cells, Biotechnology, Stem cells, Cloning, Developmental biology

The system, called partial least squares regression (PLSR), is able to predict which stem cell donors and manipulation methods might yield the best therapies for these patients.

Key Points: 
  • The system, called partial least squares regression (PLSR), is able to predict which stem cell donors and manipulation methods might yield the best therapies for these patients.
  • These studies can identify optimal donors and stem cell manipulations predicted to improve exosome function before performing in vivo experiments."
  • By bridging stem cell research and clinical trials, SCTM will help move applications of these critical investigations closer to accepted best practices.
  • RMF pursues its mission by producing its flagship World Stem Cell Summit, honouring leaders through the Stem Cell and Regenerative Medicine Action Awards, and promoting educational initiatives.

The Asia-Pacific stem cell market is anticipated to rise with the fastest CAGR of 9.89% over the projected years of 2019-2027

Retrieved on: 
Wednesday, July 31, 2019
Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Induced stem cells, Cloning, Developmental biology

The Asia-Pacific stem cell market is anticipated to rise with the fastest CAGR of 9.89% over the projected years of 2019-2027.

Key Points: 
  • The Asia-Pacific stem cell market is anticipated to rise with the fastest CAGR of 9.89% over the projected years of 2019-2027.
  • Chronic diseases like cancers have seen a considerable rise in the Asia Pacific region.
  • As a result, the demand for stem cell market is further expected to rise in this region.
  • The China stem cell market contributed significant amounts of revenue share in 2018.A growing elderly population and fundamental progress in clinical stem cell research are factors which are majorly driving this country's growth.

Molecular Devices Introduces the FLIPR Penta System

Retrieved on: 
Wednesday, July 31, 2019
Branches of biology, Biology, Life sciences, Induced stem cells, Stem cells, Biotechnology, Developmental biology, Cell biology, Induced pluripotent stem cell

SAN JOSE, Calif., July 31, 2019 /PRNewswire-PRWeb/ --Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the launch of the next generation of its FLIPR Penta High-Throughput Cellular Screening System.

Key Points: 
  • SAN JOSE, Calif., July 31, 2019 /PRNewswire-PRWeb/ --Molecular Devices, LLC, a leader in protein and cell biology technologies, today announced the launch of the next generation of its FLIPR Penta High-Throughput Cellular Screening System.
  • The new FLIPR Penta system builds on the success of the industry-leading FLIPR platform for monitoring of G-protein-coupled receptors (GPCRs) and ion channels, offering a new high-speed camera option capable of capturing key dynamics of induced pluripotent stem cell (iPSC)-derived neuronal and cardiac cells at higher frame resolution.
  • Additionally, the new ScreenWorks Peak Pro 2 software adds capabilities to translate these higher resolution signals into key insights, adding over 30 new measurements to the analysis package.
  • "The expanded capabilities of the FLIPR Penta System will allow scientists studying stem cell-derived neuronal and cardiac cells to better characterize physiologic effects of compounds," explains Sarah Vargas-Hurlston, Sr. Director of Product Marketing at Molecular Devices.

FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering Online Seminar

Retrieved on: 
Tuesday, July 16, 2019
Branches of biology, Biology, Life sciences, Stem cells, Emerging technologies, Biotechnology, Induced stem cells, Regenerative biomedicine, Stem-cell therapy, Food and Drug Administration, Tissue engineering, Regenerative medicine

DUBLIN, July 16, 2019 /PRNewswire/ -- The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 16, 2019 /PRNewswire/ -- The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.
  • This Seminar will provide a historical context for the use of stem cells in medicine, where the field has been and where it is going.
  • It will also provide a few examples of FDA approved the use of stem cells in medicine and what is needed for the field to progress.
  • Learn the fundamentals of stem cells and the FDA's regulatory approach for its use in medicine.

Online Seminar: FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering (July 18-19, 2019) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, July 16, 2019
Biotechnology, Health, Stem cells, Pharmaceutical, Branches of biology, Biology, Life sciences, Stem cells, Biotechnology, Emerging technologies, Induced stem cells, Regenerative biomedicine, Stem-cell therapy, Regenerative medicine, Food and Drug Administration, Tissue engineering

The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "FDA's Regulation of Regenerative Medicine including Stem Cell Treatments and Tissue Engineering" training has been added to ResearchAndMarkets.com's offering.
  • This Seminar will provide a historical context for the use of stem cells in medicine, where the field has been and where it is going.
  • It will also provide a few examples of FDA approved the use of stem cells in medicine and what is needed for the field to progress.
  • Learn the fundamentals of stem cells and the FDA's regulatory approach for its use in medicine.

Mesenchymal Stem Cells Advances & Applications, 2019 - Opportunities for MSC Equipment and Media System Developers

Retrieved on: 
Friday, July 12, 2019
Branches of biology, Biology, Life sciences, Stem cells, Mesenchymal stem cell, Chondrocyte, Osteoblast, Cellular differentiation, Adipocyte, Regenerative medicine, Dental pulp stem cells, Induced stem cells

DUBLIN, July 12, 2019 /PRNewswire/ -- The "Mesenchymal Stem Cells - Advances & Applications, 2019" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 12, 2019 /PRNewswire/ -- The "Mesenchymal Stem Cells - Advances & Applications, 2019" report has been added to ResearchAndMarkets.com's offering.
  • Mesenchymal stem cells (MSCs) are multipotent cells that can differentiate into a variety of cell types, including osteoblasts, chondrocytes, myocytes, adipocytes, and potentially other cell types.
  • MSCs are advantageous over other stem cells types for a variety of reasons, including that they are immuno-privileged, making them an advantageous cell type for allogenic transplantation.
  • As the most common stem cell type being used within regenerative medicine, there is huge potential for growth within the MSC market.